NEUTRON BRACHYTHERAPY IS BETTER THAN CONVENTIONAL RADIOTHERAPY IN ADVANCED CERVICAL CANCER

Y. Maruyama; J. R.Van Nagell; E. Donaldson; J. L. Beach; A. Martin; R. Kryscio; J. Yoneda; M. Hanson; J. M. Feola; C. Parker

doi:10.1016/S0140-6736(85)92430-4

NEUTRON BRACHYTHERAPY IS BETTER THAN CONVENTIONAL RADIOTHERAPY IN ADVANCED CERVICAL CANCER

Y. Maruyama
, J. R.Van Nagell
, E. Donaldson
, J. L. Beach
, A. Martin
, R. Kryscio
, J. Yoneda
, M. Hanson
, J. M. Feola
, C. Parker

Producción científica: Article › revisión exhaustiva

16 Citas (Scopus)

Resumen

Californium-252 (²⁵²Cf), a fast-neutron emitting radioisotope, was used for neutron brachytherapy (NT) of 82 patients with advanced (stage III and IV) cervical cancer. The results were compared with caesium-137 brachytherapy; both isotopes were given in combination with high-dose fractionated pelvic radiotherapy. In patients with stage IIIB disease (ie, tumour to the pelvic side-wall), ²⁵²Cfintracavitary therapy resulted in 54% 5-year survival compared with 12% in the caesium group. To be effective, Cf-NT must be given before external beam (photon) therapy.

Idioma original	English
Páginas (desde-hasta)	1120-1122
Número de páginas	3
Publicación	The Lancet
Volumen	325
N.º	8438
DOI	https://doi.org/10.1016/S0140-6736(85)92430-4
Estado	Published - may 18 1985

Nota bibliográfica

Funding Information:
We thank the US Department of Energy for the 252 caused in this study and the American Cancer Society for financial support of the ongoing randomised clinical trial. We thank Mrs Angela Sandifer for expert assistance. Correspondence should be addressed to Y. M., Department of Radiation Medicine, Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky 40536-0084, USA.

Financiación

We thank the US Department of Energy for the 252 caused in this study and the American Cancer Society for financial support of the ongoing randomised clinical trial. We thank Mrs Angela Sandifer for expert assistance. Correspondence should be addressed to Y. M., Department of Radiation Medicine, Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky 40536-0084, USA.

Financiadores
US Department of Energy
American Cancer Society-Michigan Cancer Research Fund

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Good health and well being

ASJC Scopus subject areas

General Medicine

Acceder al documento

10.1016/S0140-6736(85)92430-4

Otros archivos y enlaces

Citar esto

@article{e0b658560f454d918808c7e2d0994926,

title = "NEUTRON BRACHYTHERAPY IS BETTER THAN CONVENTIONAL RADIOTHERAPY IN ADVANCED CERVICAL CANCER",

abstract = "Californium-252 (252Cf), a fast-neutron emitting radioisotope, was used for neutron brachytherapy (NT) of 82 patients with advanced (stage III and IV) cervical cancer. The results were compared with caesium-137 brachytherapy; both isotopes were given in combination with high-dose fractionated pelvic radiotherapy. In patients with stage IIIB disease (ie, tumour to the pelvic side-wall), 252Cfintracavitary therapy resulted in 54\% 5-year survival compared with 12\% in the caesium group. To be effective, Cf-NT must be given before external beam (photon) therapy.",

author = "Y. Maruyama and Nagell, \{J. R.Van\} and E. Donaldson and Beach, \{J. L.\} and A. Martin and R. Kryscio and J. Yoneda and M. Hanson and Feola, \{J. M.\} and C. Parker",

note = "Funding Information: We thank the US Department of Energy for the 252 caused in this study and the American Cancer Society for financial support of the ongoing randomised clinical trial. We thank Mrs Angela Sandifer for expert assistance. Correspondence should be addressed to Y. M., Department of Radiation Medicine, Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky 40536-0084, USA.",

year = "1985",

month = may,

day = "18",

doi = "10.1016/S0140-6736(85)92430-4",

language = "English",

volume = "325",

pages = "1120--1122",

number = "8438",

}

TY - JOUR

T1 - NEUTRON BRACHYTHERAPY IS BETTER THAN CONVENTIONAL RADIOTHERAPY IN ADVANCED CERVICAL CANCER

AU - Maruyama, Y.

AU - Nagell, J. R.Van

AU - Donaldson, E.

AU - Beach, J. L.

AU - Martin, A.

AU - Kryscio, R.

AU - Yoneda, J.

AU - Hanson, M.

AU - Feola, J. M.

AU - Parker, C.

N1 - Funding Information: We thank the US Department of Energy for the 252 caused in this study and the American Cancer Society for financial support of the ongoing randomised clinical trial. We thank Mrs Angela Sandifer for expert assistance. Correspondence should be addressed to Y. M., Department of Radiation Medicine, Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky 40536-0084, USA.

PY - 1985/5/18

Y1 - 1985/5/18

N2 - Californium-252 (252Cf), a fast-neutron emitting radioisotope, was used for neutron brachytherapy (NT) of 82 patients with advanced (stage III and IV) cervical cancer. The results were compared with caesium-137 brachytherapy; both isotopes were given in combination with high-dose fractionated pelvic radiotherapy. In patients with stage IIIB disease (ie, tumour to the pelvic side-wall), 252Cfintracavitary therapy resulted in 54% 5-year survival compared with 12% in the caesium group. To be effective, Cf-NT must be given before external beam (photon) therapy.

AB - Californium-252 (252Cf), a fast-neutron emitting radioisotope, was used for neutron brachytherapy (NT) of 82 patients with advanced (stage III and IV) cervical cancer. The results were compared with caesium-137 brachytherapy; both isotopes were given in combination with high-dose fractionated pelvic radiotherapy. In patients with stage IIIB disease (ie, tumour to the pelvic side-wall), 252Cfintracavitary therapy resulted in 54% 5-year survival compared with 12% in the caesium group. To be effective, Cf-NT must be given before external beam (photon) therapy.

UR - https://www.scopus.com/pages/publications/0021857978

UR - https://www.scopus.com/pages/publications/0021857978#tab=citedBy

U2 - 10.1016/S0140-6736(85)92430-4

DO - 10.1016/S0140-6736(85)92430-4

M3 - Article

C2 - 2860334

AN - SCOPUS:0021857978

SN - 0140-6736

VL - 325

SP - 1120

EP - 1122

JO - The Lancet

JF - The Lancet

IS - 8438

ER -

NEUTRON BRACHYTHERAPY IS BETTER THAN CONVENTIONAL RADIOTHERAPY IN ADVANCED CERVICAL CANCER

Resumen

Nota bibliográfica

Financiación

ODS de las Naciones Unidas

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto